Skip to content

OnyxBiotech News

Subscribe About Onyx
Cell & Gene Leaders Live Sunday 15 November 2026 · The Shard (Shangri-La), London · One-day summit for cell & gene therapy leaders Sunday 15 November 2026 · The Shard (Shangri-La), London Get tickets → London Life Sciences Week Guide The unofficial London Life Sciences Week Guide, published by Onyx Newsroom · Every event 15–19 November 2026 Every event 15–19 November 2026 · Published by Onyx Newsroom Plan your week →
Live Interviews Editor's pick

Onyx @ Jefferies: David Chang, CEO, Allogene

Cema-cel is already in the pivotal Phase 2 ALPHA3 frontline lymphoma trial, with manufacturing capacity sized for tens of thousands of annual doses (up to ~60,000 across products).

Dr. Adil Ali
Published
1 min read
Table of Contents

📈 Stock

Allogene Therapeutics
NASDAQ: ALLO
Data and chart by TradingView.

If off-the-shelf CAR-T works, the economics of oncology will be rewritten - and Allogene Therapeutics is arguably closest to that inflection point.

Cema-cel is already in the pivotal Phase 2 ALPHA3 frontline lymphoma trial, with manufacturing capacity sized for tens of thousands of annual doses (up to ~60,000 across products).

Their 2026 interim data will test whether fast, donor-derived CAR-T can deliver autologous-level durability at a fraction of the cost and cycle time.

If this thesis holds, Allogene's CAR-T platform will shift from a scientific bet to one of the highest-leverage commercial opportunities in cell therapy.

I caught up with CEO Dr. David Chang at Jefferies to find out more.

I hope you enjoy watching!

Yours sincerely,
Dr. Adil Ali

Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments

More Live Interviews ↗